Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis
Kaleen N. Hayes,
Ulrike Baschant,
Barbara Hauser,
Barbara Hauser,
Andrea M. Burden,
Elizabeth M. Winter
Affiliations
Kaleen N. Hayes
Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States
Ulrike Baschant
Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
Barbara Hauser
Rheumatic Disease Unit, Western General Hospital, National Health Service (NHS) Lothian, Edinburgh, United Kingdom
Barbara Hauser
Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
Andrea M. Burden
Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology [Eidgenössische Technische Hochschule (ETH)] Zurich, Zurich, Switzerland
Elizabeth M. Winter
Center for Bone Quality, Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands